Skip to main content

Research Repository

Advanced Search

All Outputs (134)

Prognostic stratification of oestrogen receptor-positive HER2-negative lymph node-negative class of breast cancer (2016)
Journal Article
Rakha, E. A., Agarwal, D., Green, A. R., Ashankyty, I., Ellis, I. O., Ball, G., & Alaskandarany, M. A. (2017). Prognostic stratification of oestrogen receptor-positive HER2-negative lymph node-negative class of breast cancer. Histopathology, 70(4), 622-631. https://doi.org/10.1111/his.13108

Aims Multigene assay is recommended currently for prognostic stratification of the clinically indeterminate group of breast cancer (BC) patients defined as lymph node (LN)‐negative, oestrogen receptor (ER)‐positive, HER2‐negative (LN−/ER+/HER2−) t... Read More about Prognostic stratification of oestrogen receptor-positive HER2-negative lymph node-negative class of breast cancer.

Molecular classification of breast cancer: what the pathologist needs to know (2016)
Journal Article
Rakha, E. A., & Green, A. R. (2017). Molecular classification of breast cancer: what the pathologist needs to know. Pathology, 49(2), 111-119. https://doi.org/10.1016/j.pathol.2016.10.012

Breast cancer is a heterogeneous disease featuring distinct histological, molecular and clinical phenotypes. Although traditional classification systems utilising clinicopathological and few molecular markers are well established and validated, they... Read More about Molecular classification of breast cancer: what the pathologist needs to know.

Breast conservation in ductal carcinoma in situ (DCIS): what defines optimal margins? (2016)
Journal Article
Toss, M. S., Pinder, S. E., Green, A. R., Thomas, J., Morgan, D. A., Robertson, J. F., …Rakha, E. A. (2017). Breast conservation in ductal carcinoma in situ (DCIS): what defines optimal margins?. Histopathology, 70(5), 681-692. https://doi.org/10.1111/his.13116

The introduction of mammographic screening has resulted in a rise in the detection rate of ductal carcinoma in situ (DCIS), currently accounting for one‐fifth of screen‐detected breast cancers. Although 60–70% of DCIS are treated with breast‐conservi... Read More about Breast conservation in ductal carcinoma in situ (DCIS): what defines optimal margins?.

Caspase-3 and caspase-8 expression in breast cancer: caspase-3 is associated with survival (2016)
Journal Article
Xuan, P., Storr, S. J., Zhang, Y., Rakha, E., Green, A. R., Ellis, I. O., & Martin, S. G. (in press). Caspase-3 and caspase-8 expression in breast cancer: caspase-3 is associated with survival. Apoptosis, https://doi.org/10.1007/s10495-016-1323-5

Impaired apoptosis is one of the hallmarks of cancer. Caspase-3 and -8 are key regulators of the apoptotic response and have been shown to interact with the calpain family, a group of cysteine proteases, during tumorigenesis. The current study sought... Read More about Caspase-3 and caspase-8 expression in breast cancer: caspase-3 is associated with survival.

Clinicopathological and prognostic significance of mitogen-activated protein kinases (MAPK) in breast cancers (2016)
Journal Article
Ahmad, D. A. J., Negm, O. H., Layth Alabdullah, M., Mirza, S., Hamed, M. R., Band, V., …Rakha, E. (2016). Clinicopathological and prognostic significance of mitogen-activated protein kinases (MAPK) in breast cancers. Breast Cancer Research and Treatment, 159(3), 457-467. https://doi.org/10.1007/s10549-016-3967-9

Background Mitogen-activated protein kinases (MAPKs) are signalling transduction molecules that have different functions and diverse behaviour in cancer. In breast cancer, MAPK is related to oestrogen receptor (ER) and HER2. Methods Protein express... Read More about Clinicopathological and prognostic significance of mitogen-activated protein kinases (MAPK) in breast cancers.

Impact of tissue sampling on accuracy of Ki67 immunohistochemistry evaluation in breast cancer (2016)
Journal Article
Besusparis, J., Plancoulaine, B., Rasmusson, A., Augulis, R., Green, A. R., Ellis, I. O., …Laurinavicius, A. (2016). Impact of tissue sampling on accuracy of Ki67 immunohistochemistry evaluation in breast cancer. Diagnostic Pathology, 11(1), Article 82. https://doi.org/10.1186/s13000-016-0525-z

Background: Gene expression studies have identified molecular subtypes of breast cancer with implications to chemotherapy recommendations. For distinction of these types, a combination of immunohistochemistry (IHC) markers, including proliferative ac... Read More about Impact of tissue sampling on accuracy of Ki67 immunohistochemistry evaluation in breast cancer.

Overexpression of specific CD44 isoforms is associated with aggressive cell features in acquired endocrine resistance (2016)
Journal Article
Bellerby, R., Smith, C., Kyme, S., Gee, J., Günthert, U., Green, A., …Hiscox, S. (2016). Overexpression of specific CD44 isoforms is associated with aggressive cell features in acquired endocrine resistance. Frontiers in Oncology, 6, Article 145. https://doi.org/10.3389/fonc.2016.00145

While endocrine therapy is the mainstay of ER+ breast cancer, the clinical effectiveness of these agents is limited by the phenomenon of acquired resistance that is associated with disease relapse and poor prognosis. Our previous studies revealed tha... Read More about Overexpression of specific CD44 isoforms is associated with aggressive cell features in acquired endocrine resistance.

SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis (2016)
Journal Article
Abdel-Fatah, T. M., Agarwal, D., Liu, D.-X., Russell, R., Rueda, O. M., Liu, K., …Chan, S. Y. (2016). SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis. Lancet Oncology, 17(7), 1004-1018. https://doi.org/10.1016/S1470-2045%2816%2900174-1

Background: Proliferation markers and profiles have been recommended for guiding the choice of systemic treatments for breast cancer. However, the best molecular marker or test to use has not yet been identified. We did this study to identify factors... Read More about SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis.

The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes (2016)
Journal Article
Pereira, B., Chin, S.-F., Rueda, O. M., Vollan, H.-K. M., Provenzano, E., Bardwell, H. A., …Caldas, C. (in press). The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nature Communications, 7, Article 11479. https://doi.org/10.1038/ncomms11479

The genomic landscape of breast cancer is complex, and inter- and intra-tumour heterogeneity are important challenges in treating the disease. In this study, we sequence 173 genes in 2,433 primary breast tumours that have copy number aberration (CNA)... Read More about The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes.

Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer (2016)
Journal Article
Green, A. R., Soria, D., Powe, D. G., Nolan, C. C., Aleskandarany, M. A., Szász, M., …Ellis, I. O. (2016). Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer. Breast Cancer Research and Treatment, 157(1), 65-75. https://doi.org/10.1007/s10549-016-3804-1

The Nottingham prognostic index plus (NPI+) is based on the assessment of biological class combined with established clinicopathologic prognostic variables providing improved patient outcome stratification for breast cancer superior to the traditiona... Read More about Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer.

MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours (2016)
Journal Article
Green, A. R., Aleskandarany, M. A., Agarwal, D., Elsheikh, S., Nolan, C. C., Diez-Rodriguez, M., …Rakha, E. A. (2016). MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours. British Journal of Cancer, 114(8), 917-928. https://doi.org/10.1038/bjc.2016.46

Background: MYC is amplified in approximately 15% of breast cancers (BCs) and is associated with poor outcome. c-MYC protein is multi-faceted and participates in many aspects of cellular function and is linked with therapeutic response in BCs. We... Read More about MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours.

ELF5 drives lung metastasis in luminal breast cancer through recruitment of Gr1+ CD11b+ myeloid-derived suppressor cells (2015)
Journal Article

During pregnancy, the ETS transcription factor ELF5 establishes the milk-secreting alveolar cell lineage by driving a cell fate decision of the mammary luminal progenitor cell. In breast cancer, ELF5 is a key transcriptional determinant of tumor subt... Read More about ELF5 drives lung metastasis in luminal breast cancer through recruitment of Gr1+ CD11b+ myeloid-derived suppressor cells.

Clinicopathological and prognostic significance of RECQL5 helicase expression in breast cancers (2015)
Journal Article
Arora, A., Abdel-Fatah, T. M., Agarwal, D., Doherty, R., Croteau, D. L., Moseley, P. M., …Madhusudan, S. (2016). Clinicopathological and prognostic significance of RECQL5 helicase expression in breast cancers. Carcinogenesis, 37(1), 63-71. https://doi.org/10.1093/carcin/bgv163

RECQL5 is a member of the RecQ family of DNA helicases and has key roles in homologous recombination, base excision repair, replication and transcription. The clinicopathological significance of RECQL5 expression in breast cancer is unknown. In this... Read More about Clinicopathological and prognostic significance of RECQL5 helicase expression in breast cancers.

Nottingham Prognostic Index Plus: validation of a clinical decision making tool in breast cancer in an independent series (2015)
Journal Article
Green, A. R., Soria, D., Stephen, J., Powe, D. G., Nolan, C. C., Kunkler, I., …Ellis, I. O. (2016). Nottingham Prognostic Index Plus: validation of a clinical decision making tool in breast cancer in an independent series. Journal of Pathology: Clinical Research, 2, https://doi.org/10.1002/cjp2.32

The Nottingham Prognostic Index Plus (NPI+)is a clinical decision making tool in breast cancer (BC) that aims to provide improved patient outcome stratification superior to the traditional NPI. This study aimed to validate the NPI+ in an independent... Read More about Nottingham Prognostic Index Plus: validation of a clinical decision making tool in breast cancer in an independent series.

Ki67/SATB1 ratio is an independent prognostic factor of overall survival in patients with early hormone receptor-positive invasive ductal breast carcinoma (2015)
Journal Article
Laurinavicius, A., Green, A. R., Laurinaviciene, A., Smailyte, G., Ostapenko, V., Meskauskas, R., & Ellis, I. O. (2015). Ki67/SATB1 ratio is an independent prognostic factor of overall survival in patients with early hormone receptor-positive invasive ductal breast carcinoma. Oncotarget, 6(38), 41134-41145. https://doi.org/10.18632/oncotarget.5838

Biological diversity of breast cancer presents challenges for personalized therapy and necessitates multiparametric approaches to understand and manage the disease. Multiple protein biomarkers tested by immunohistochemistry (IHC), followed by digital... Read More about Ki67/SATB1 ratio is an independent prognostic factor of overall survival in patients with early hormone receptor-positive invasive ductal breast carcinoma.

PKC? attenuates jagged-1-mediated notch signaling in ErbB-2-positive breast cancer to reverse trastuzumab resistance (2015)
Journal Article

Purpose: Breast cancer is the second leading cause of cancer mortality among women worldwide. The major problem with current treatments is tumor resistance, recurrence, and disease progression. ErbB-2–positive breast tumors are aggressive and frequen... Read More about PKC? attenuates jagged-1-mediated notch signaling in ErbB-2-positive breast cancer to reverse trastuzumab resistance.

Construction of tissue microarrays from core needle biopsies: a systematic literature review (2015)
Journal Article
Albanghali, M., Green, A., Rakha, E., Aleskandarany, M., Nolan, C., Ellis, I., & Cheung, K.-L. (2016). Construction of tissue microarrays from core needle biopsies: a systematic literature review. Histopathology, 68(3), 323-332. https://doi.org/10.1111/his.12802

In some clinical circumstances, core needle biopsy (CNB) may be the only source of material from cancer tissue for diagnostic use. The volume of tissue available in a CNB is low, and opportunities for research use can therefore be limited. The tissue... Read More about Construction of tissue microarrays from core needle biopsies: a systematic literature review.

The pioneer factor PBX1 is a novel driver of metastatic progression in ERα-positive breast cancer (2015)
Journal Article
Magnani, L., Patten, D. K., Nguyen, V. T. M., Hong, S.-P., Steel, J. H., Patel, N., …Coombes, C. R. (2015). The pioneer factor PBX1 is a novel driver of metastatic progression in ERα-positive breast cancer. Oncotarget, 6(26), 21878-21891. https://doi.org/10.18632/oncotarget.4243

Over 30% of ERα breast cancer patients develop relapses and progress to metastatic disease despite treatment with endocrine therapies. The pioneer factor PBX1 translates epigenetic cues and mediates estrogen induced ERα binding. Here we demonstrate t... Read More about The pioneer factor PBX1 is a novel driver of metastatic progression in ERα-positive breast cancer.